Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer

NCT00546130 is registered in ClinicalTrials.gov with University of Toyama as lead sponsor.

NCT NCT00546130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00546130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer
Lead sponsor
University of Toyama
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2007
Completion date
September 30, 2011
Enrollment
45 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer